Giovanna Pecoraro

Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Imaging and Clinical Correlates of [177Lu]Lu-PSMA PET-Defined Eligibility in De Novo Metastatic Prostate Cancer.

Imaging and Clinical Correlates of [177Lu]Lu-PSMA PET-Defined Eligibility in De Novo Metastatic Prostate Cancer.

Journal: Biomedicines
Published: July 13, 2026

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

Journal: Drugs
Published: April 16, 2026

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Journal: European urology
Published: March 23, 2026

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

Journal: European urology oncology
Published: February 20, 2026

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

Journal: European urology oncology
Published: November 11, 2025

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Journal: Cancers
Published: October 16, 2025

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Journal: Prostate cancer and prostatic diseases
Published: September 04, 2025

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Journal: Frontiers in oncology
Published: June 16, 2025

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

Journal: International journal of molecular sciences
Published: April 22, 2025

New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative review.

New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative review.

Journal: Chinese clinical oncology
Published: March 26, 2025

Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions.

Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions.

Journal: Critical reviews in oncology/hematology
Published: July 22, 2024

Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney.

Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney.

Journal: Clinical genitourinary cancer
Published: July 18, 2024
Showing 1-12 of 16

Last Updated: 09/26/2026